Elutia Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ELUT Nasdaq 2836 elutia.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Elutia Inc.

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - May 18th, 2026 2:05 pm
Elutia (ELUT) Q1 2026 Earnings Transcript - May 15th, 2026 6:58 am
Elutia Inc. Q1 2026 Earnings Call Summary - May 15th, 2026 6:30 am
Elutia Inc (ELUT) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Revenue Shifts - May 14th, 2026 11:01 pm
Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market - May 14th, 2026 2:05 pm
Elutia to Present at the 16th Annual LD Micro Invitational May 18th - May 14th, 2026 2:01 pm
Elutia to Present at the 16th Annual LD Micro Invitational on May 18th - May 14th, 2026 2:01 pm
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues - Apr 30th, 2026 2:43 pm
Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 - Apr 30th, 2026 2:05 pm
Elutia to Present at Sidoti’s Small-Cap Virtual Investor Conference March 18-19 - Mar 17th, 2026 6:00 am
Elutia Inc (ELUT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic Moves Amid ... - Mar 11th, 2026 9:00 pm
Elutia Inc. Q4 2025 Earnings Call Summary - Mar 11th, 2026 6:18 pm
Elutia (ELUT) Q4 2025 Earnings Call Transcript - Mar 11th, 2026 4:47 pm
Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process - Mar 11th, 2026 2:05 pm
Elutia Regains Compliance with Nasdaq Listing Requirements - Mar 4th, 2026 6:00 am
Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market - Mar 2nd, 2026 6:00 am
Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026 - Feb 25th, 2026 2:05 pm
Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™ - Feb 18th, 2026 6:00 am
Insider Spends US$74k Buying More Shares In Elutia - Feb 4th, 2026 3:52 am
Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones - Jan 12th, 2026 6:00 am